Direct from ESMO 2025 in Berlin, Dr. Mark Pegram and Dr. Neil Iyengar unpack what many are calling a new standard in HER2-directed therapy.

From DESTINY-Breast 11’s practice-changing neoadjuvant results to DESTINY-Breast 05 in the adjuvant setting — and now DESTINY-Breast 09 rewriting the metastatic playbook — the data are clear: trastuzumab deruxtecan (T-DXd) is transforming treatment across disease stages.

The discussion moves beyond HER2 + disease into HER2-low and ultra-low, touching on how new definitions, ADC sequencing, and precision testing could expand eligibility to the majority of breast cancers.

🎧 Tune in for a high-impact, expert-level recap of the trials defining the next chapter of HER2 oncology.

#BreastCancer #ESMO2025 #OncologyPodcast #HER2Positive #HER2Low #TDXd #Pegram #Iyengar #TrastuzumabDeruxtecan #CancerResearch #BreastOncology #PrecisionOncology #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media